New possibilities for the therapy of secondary progressive multiple sclerosis
| Autor: | I. D. Stolyarov, E. V. Ivashkova, Alexey M. Petrov |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty multiple sclerosis Placebo 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine RC346-429 Adverse effect Respiratory tract infections business.industry Multiple sclerosis secondary progression medicine.disease Clinical trial Psychiatry and Mental health Clinical Psychology Safety profile 030104 developmental biology Siponimod chemistry Secondary progressive multiple sclerosis siponimod Neurology. Diseases of the nervous system Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 11, Iss 4, Pp 125-129 (2019) |
| ISSN: | 2310-1342 2074-2711 |
| Popis: | Patients with multiple sclerosis (MS) are at high risk for transition to secondary progressive MS (SPMS). To date, there has not been a sufficiently effective therapy for SPMS. Siponimod is a selective sphingosine-1-phosphate types 1 and 5 receptor modulator that has been shown to be more effective than placebo in slowing the progression of disability in patients with SPMS in the international phase III (EXPAND) clinical trial. This review analyzes data on the pathophysiology of MS progression, the features of the mechanism of action of siponimod, the efficiency and safety of its use, including those by the results of the EXPAND study. The latter studied the efficacy of siponimod by the time to 3-month confirmed disability progression (3M-CDP) and also assessed other clinical and radiological parameters. The analysis included data on 1,651 patients with SPMS from 31 countries. In the patients who received siponimod, the risk of 3M-CDP decreased by an average of 21% compared with those who took placebo. The administration of siponimod positively affected the speed of cognitive processes. Mild adverse events associated with liver failure, hypertension, and upper respiratory tract infections were more common in the siponimod group. Siponimod did not pose a higher risk for developing malignant neoplasms. The drug reduces the risk of disability progression in patients with SPMS and has a favorable safety profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|